Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
JNJ 
Johnson & Johnson (JNJ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: JNJ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.53% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 374.39B USD | Price to earnings Ratio 26.83 | 1Y Target Price 169.07 |
Price to earnings Ratio 26.83 | 1Y Target Price 169.07 | ||
Volume (30-day avg) 9738499 | Beta 0.46 | 52 Weeks Range 138.68 - 169.99 | Updated Date 04/2/2025 |
52 Weeks Range 138.68 - 169.99 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 3.24% | Basic EPS (TTM) 5.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.84% | Operating Margin (TTM) 18.15% |
Management Effectiveness
Return on Assets (TTM) 8.13% | Return on Equity (TTM) 20.06% |
Valuation
Trailing PE 26.83 | Forward PE 14.47 | Enterprise Value 381421164469 | Price to Sales(TTM) 4.22 |
Enterprise Value 381421164469 | Price to Sales(TTM) 4.22 | ||
Enterprise Value to Revenue 4.29 | Enterprise Value to EBITDA 15.39 | Shares Outstanding 2409850112 | Shares Floating 2403957116 |
Shares Outstanding 2409850112 | Shares Floating 2403957116 | ||
Percent Insiders 0.06 | Percent Institutions 73.49 |
Analyst Ratings
Rating 3.74 | Target Price 171.61 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 13 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Johnson & Johnson
Company Overview
History and Background
Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Initially focused on sterile surgical dressings, it expanded into consumer health, pharmaceuticals, and medical devices. Key milestones include going public in 1944 and numerous acquisitions.
Core Business Areas
- Innovative Medicine: Develops and markets pharmaceutical products addressing therapeutic areas like immunology, oncology, neuroscience, cardiovascular, and infectious diseases.
- MedTech: Offers a range of medical devices and solutions used in surgery, orthopedics, vision care, and cardiovascular care.
Leadership and Structure
The current CEO is Joaquin Duato. The company is structured into two segments: Innovative Medicine and MedTech.
Top Products and Market Share
Key Offerings
- Stelara: A biologic therapy for autoimmune diseases. Competitors include AbbVie's Humira and Skyrizi, and Amgen's Enbrel. Stelara is a major revenue generator for the Innovative Medicine segment.
- Invega Sustenna: An injectable antipsychotic medication. Competitors include other antipsychotics from companies like Eli Lilly and AstraZeneca.
- Ethicon: Surgical instruments and sutures, a major brand within MedTech. Competitors include Medtronic and Becton Dickinson.
- Acuvue: Contact lenses and vision care products. Competitors include Alcon and CooperVision.
Market Dynamics
Industry Overview
The healthcare industry is characterized by innovation, regulation, and strong growth driven by aging populations and increasing healthcare spending. Key trends include personalized medicine, digital health, and value-based care.
Positioning
Johnson & Johnson is a leading player in the healthcare industry, with a diversified portfolio, strong brand recognition, and a global presence. Its competitive advantages include its R&D capabilities, distribution network, and financial resources.
Total Addressable Market (TAM)
The global healthcare market is estimated to be in the trillions of dollars. JNJ is positioned well to capture a share via its diversified strategy.
Upturn SWOT Analysis
Strengths
- Diversified business model
- Strong brand reputation
- Extensive distribution network
- Significant R&D investment
- Strong financial position
Weaknesses
- Exposure to litigation
- Patent expirations
- Dependence on key products
- Bureaucratic structure
Opportunities
- Emerging markets growth
- Technological advancements (AI, robotics)
- Strategic acquisitions
- Expanding into new therapeutic areas
Threats
- Increased competition
- Generic drug erosion
- Regulatory changes
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- NVS
- TMO
Competitive Landscape
Johnson & Johnson's advantages include its diversified portfolio and strong brand. Disadvantages include exposure to litigation and patent expirations. Competitors like Pfizer and Merck have strong pipelines and market positions.
Major Acquisitions
Abiomed
- Year: 2022
- Acquisition Price (USD millions): 16600
- Strategic Rationale: Expanded J&J's MedTech portfolio in the cardiovascular space.
Proteologix
- Year: 2024
- Acquisition Price (USD millions): 850
- Strategic Rationale: Expanded J&J's Innovative Medicine portfolio in the immune-oncology space.
Growth Trajectory and Initiatives
Historical Growth: Johnson & Johnson has experienced moderate growth over the past decade, driven by new product launches and acquisitions.
Future Projections: Analysts project continued growth for Johnson & Johnson, driven by its pharmaceutical and medical device segments.
Recent Initiatives: Recent initiatives include strategic acquisitions, R&D investments in key therapeutic areas, and cost-cutting measures.
Summary
Johnson & Johnson is a stable, diversified healthcare giant with a strong track record. Its diversified business model and R&D capabilities drive growth. However, litigation risks and patent expirations remain challenges. Strategic acquisitions and a focus on emerging markets are key to future success.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
DHR
Danaher Corporation
DHR
Danaher Corporation
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
- Company Website
- Earnings Call Transcripts
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Johnson & Johnson
Exchange NYSE | Headquaters New Brunswick, NJ, United States | ||
IPO Launch date 1944-09-24 | CEO & Chairman Mr. Joaquin Duato | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 138100 | Website https://www.jnj.com |
Full time employees 138100 | Website https://www.jnj.com | ||
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.